Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial

DSpace Repository

Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial

Author: Weisel, Katja; Dimopoulos, Meletios; Song, Kevin W.; Moreau, Philippe; Palumbo, Antonio; Belch, Andrew; Schey, Stephen; Sonneveld, Pieter; Sternas, Lars; Yu, Xin; Amatya, Ramesh; Gibson, Craig J.; Zaki, Mohamed; Jacques, Christian; San Miguel, Jesus
Tübinger Autor(en):
Weisel, Katja
Published in: Clinical Lymphoma Myeloma & Leukemia (2015), Bd. 15, H. 9, S. 519-530
Verlagsangabe: Cig Media Group
Language: English
Full text: http://dx.doi.org/10.1016/j.clml.2015.05.007
ISSN: 2152-2650
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)